Suppose one supplier quotes individual trocar packs and another quotes a kit with shared obturators. Both bids show a nominal diameter and a regulatory reference, but the working lengths, reducers and contents differ. This is an illustrative purchasing scenario, not a report of two actual supplier bids. The immediate task is to establish what each price buys and what evidence supports that configuration.
A useful comparison should end in a decision for each offered line: proceed to a defined evaluation, ask a named person for missing evidence, or hold the line because a requirement is unmet. The schedule below joins product details to documents and reviewer responsibility. It does not certify a supplier or rank brands.
Which dimensions and instrument interfaces belong on the trocar quotation?
A nominal size is not a dimensional drawing. A 2024 descriptive study obtained dimensions for 125 single-use trocars from nine vendors and found differences within marketed size categories. The original abstract reports limited public access to actual dimensions. These findings support asking for drawings; they do not establish that a particular current model fails an instrument-fit requirement.18
Separate the usable instrument passage, outer cannula profile and working length. Ask the supplier to define its measurement points, tolerances and supported instrument range. A diameter attached to a shaft in one document should not silently become a guaranteed internal clearance in your comparison. Record the exact instrument model and relevant manufacturer instructions alongside the proposed access device.
Real catalog examples show why configuration matters. CITEC lists optical reference CIT-GT-03 as 3 × 65 mm, bladeless CIT-WT-12 as 12 × 100 mm and longer bladeless CIT-WTL-12 as 12 × 150 mm. These are vendor-declared specifications checked on 24 October 2026, not independently measured dimensions, clinical recommendations or findings about market authorization.9
| Field | Supplier response needed | Buyer review |
|---|---|---|
| Nominal diameter and actual dimensions | Define the size label; provide internal and external dimensions, tolerances and the supported instrument range. | Check against the approved instrument list; do not infer fit from matching labels.18 |
| Cannula working length | Drawing with measurement points and the exact length for the quoted reference. | Keep the chosen length tied to the clinical team’s requirements; do not substitute an overall assembly length. |
| Instrument and optical interface | Named instruments, scope models and any restrictions in the respective IFUs. | Request evidence for the proposed combination; an optical channel is not a universal scope interface.15 |
| Seal, reducer and gas connection | Supported range, reducer parts, valve/stopcock arrangement and connection instructions. | Verify what is included and what needs separate supply; agree configuration-specific evaluation. |
| Unit of sale | Contents per sterile pack, packs per box and price basis. | Normalize the quote to the agreed configuration before comparing totals. |
Source: Editorial RFQ recommendations. Dimensional caution: Limperg et al. (2024); interface caution: the device-specific Stryker IFU. No universal size range or acceptance limit is asserted.
The clinician-approved instrument plan should precede stock consolidation. A procurement team can document required combinations and identify omissions; it should not use this table to choose a port size or cannula length for a patient. If a manufacturer offers a substitute model, reopen the affected fields instead of accepting “same size” as the complete justification.
How do tip design, visualization and cannula fixation differ?
Use separate columns for the obturator’s tip mechanism, optical capability and cannula fixation. For example, the Stryker IFU describes bladeless optical obturators with a clear tip and video-laparoscopy channel, as well as smooth or threaded sleeves. That document concerns distributed reprocessed devices for single use. Its instructions apply to those devices and are not permission to reprocess a different single-use product.15
Public supplier guides already explain common size and tip options: Ezisurg discusses the instrument plan; Senmed compares bladeless and classic designs; Changfeng offers a selection framework. Those are commercial descriptions, useful for understanding the offer but insufficient on their own to verify clinical superiority or compatibility.14, 16, 17
| Feature axis | What to record | Evidence question |
|---|---|---|
| Tip mechanism | Manufacturer’s exact bladed, bladeless or blunt-tip description for the offered model. | Does the current device description or IFU support the quoted design? Avoid inferring a safety benefit from the name. |
| Visualization | Optical or non-optical; supported scope and any viewing-interface restrictions. | What combination is documented, and what remains to be evaluated?15 |
| Cannula fixation | Declared sleeve geometry and any supplied fixation accessories. | What configuration was assessed? A component snap-retention result is not automatically tissue fixation evidence.1, 2 |
| Seal and reducer | Declared instrument range, removable parts and replacement/accessory references. | Does the evidence cover the configuration actually being quoted? |
| Packaging | Individual device, cannula-only pack or defined multi-component kit. | Are the obturator, cannula and accessory counts explicit? |
Source: Editorial comparison framework informed by the FDA device descriptions and the Stryker IFU. These axes describe an offer; they are not clinical rankings.
A supplier calling a device “optical” has answered a visualization question, not every question about its tip, seal or fixation. Conversely, “bladeless” does not tell you which laparoscope fits. Have the supplier complete the fields separately, preserving its exact terminology where a translation could obscure a design difference.
What seal, reducer and retention evidence should a buyer request?
The applicant summaries for K231042 and K190029 list bench evaluations of instrument insertion/removal force, leak resistance and snap-feature retention. They also describe porcine-model evaluations of penetration and fixation; K190029 includes optical visualization. These are different test categories. A housing snap test cannot be relabeled as a cannula pull-out test in tissue, and neither summary supplies a universal acceptance threshold for all trocars.1, 2
Request the report identifier and revision, tested references, sample basis, conditioning, apparatus, method, acceptance criteria and results. Ask how the manufacturer links the tested configuration to the quoted model. Where testing covers a representative family member, the rationale for that choice matters as much as a statement that the test passed. These are proposed procurement controls, not a claim that every public summary contains the full report.
- Leak evidence: Ask which valve and reducer arrangement was tested, whether a device was present in the channel, the test conditions and how results were measured. Let qualified reviewers assess relevance; do not copy a pressure or leakage limit from an unrelated product.
- Instrument passage and force: Identify the actual test instruments or fixtures, insertion/removal conditions and any restrictions. A bore dimension alone does not document the complete instrument–seal interaction.
- Retention: Identify whether the report concerns a component connection, the obturator–cannula lock or fixation in a tissue model. Keep the endpoints separate when comparing suppliers.
- Change coverage: Ask which changes to seals, reducers, materials, geometry or supplied accessories would require reassessment and buyer notification.
Public summaries are useful for deciding what to request, but they do not independently reproduce a factory’s results. If a supplier cannot share a complete confidential report, ask whether a controlled extract, traceable report summary or qualified review can resolve the requirement. Record remaining uncertainty instead of presenting an unperformed test as a pass.
What changes when the quotation contains a kit rather than singles?
Start with the bill of materials and price unit. CITEC’s catalog lists CIT-GT-KIT05 with two 5 mm cannulas and one 5 mm obturator. That named example demonstrates why a kit count is not necessarily an obturator count; it does not prescribe a port set or establish that sharing is suitable for a particular clinical workflow.9
Ask the clinical team to review the offered contents and the relevant instructions before procurement standardizes the pack. Identify any missing component, redundant accessory or separately priced item. Do not infer a contamination event, a time saving or a cost advantage simply because a kit has shared components.
| Decision | Individual packs | Defined kit | What to resolve |
|---|---|---|---|
| Contents | Verify whether each pack contains a complete trocar or only a component. | List every cannula, obturator, reducer and accessory. | Record counts and references; have the clinical team approve the configuration. |
| Stock flexibility | Separate references may support different order mixes. | A fixed bill of materials ties replenishment to that composition. | Compare forecast use, storage and substitution rules. |
| Cost basis | Include all items needed for the agreed configuration. | Include any additional items and unused-content costs. | Compare complete offers; no price or savings percentage is assumed. |
| Evidence | Link each offered reference to its documentation. | Identify the pack’s responsible organization and configuration evidence. | Obtain the applicable pack documentation; individual component documents may not complete the review. |
| Alternatives | Consider the institution’s approved product options. | Check whether the offer includes reusable or hybrid components. | Evaluate the whole local workflow rather than assuming single-use always wins.13 |
Source: Editorial purchasing framework. NHS Supply Chain’s current framework includes trocar and procedure-kit lots and reusable/reposable options; it does not establish these offers’ relative costs.
For the distinct US convenience-kit and EU procedure-pack questions, use the sterile procedure kit regulatory guide. This article’s task is to identify the quoted contents, responsible organization and unresolved evidence questions. It does not assume every kit uses the same legal route or sterilization method.
How should the quoted configuration match its market evidence?
For a US offer, identify the applicant, subject device, intended use and supporting configuration description in the actual clearance record. The two examples here use product code GCJ and Class II under 21 CFR 876.1500. GCJ is a broader laparoscope/accessory classification, not a census of disposable trocar manufacturers. A product code alone does not identify a cleared offered model.1, 2, 10
K231042: The FDA letter is dated 8 June 2023. The applicant’s proposed-device tables list bladeless shaft diameters of 5, 10, 12 and 15 mm, and bladed diameters of 5, 10 and 12 mm, with 100 mm shafts. The proposed indication is abdominal and gynecologic access. The predicate columns include different dimensions and a thoracic indication. Read those columns separately; they do not extend the subject device’s documented scope.1
K190029: The database and clearance letter name five families, including blunt-tip and spiral trocars. The linked indications form and detailed summary describe bladeless, optical and bladed devices. This is a public-document reconciliation question. Ask the manufacturer to explain how the exact offer relates to the cleared device and current labeling. The mismatch by itself does not prove that a quoted model is unauthorized.2
A public summary need not enumerate every commercial catalog number. Request a traceable manufacturer mapping and regulatory rationale when the quote, label or dimensions cannot be reconciled from the public material. The FDA 510(k) verification guide explains the broader clearance check. Keep clearance distinct from establishment registration and from approval terminology.
FDA also defines OTJ as a laparoscopic single-port access device with multiple trocars and insufflation tubing bound by a flexible foam port. Its classification record is Class II with a 510(k) route. That is a defined design category, not a reason to classify every product marketed with “single port” in its name without examining the actual device.11
China: SAMR lists YY/T 1710-2020 for single-use abdominal trocars as a current recommended industry standard, published on 26 February 2020 and implemented on 1 March 2021. Citing that standard does not demonstrate that an offered model passed its applicable tests or holds a market authorization. Ask for the underlying applicable evidence; no numerical clause limits are reproduced here.3
Keep a clinical-evaluation exemption separate from registration status. NMPA’s 2025 No. 19 notice publishes a revised exemption catalog. This guide has not established the offered product’s current exemption or registration status; neither should be inferred from a historical catalog reference or from YY/T 1710 alone.4
EU: MDCG 2021-24 Rev.1 is dated April 2026. Its non-binding guidance explains Rules 6 and 7, their Class IIa defaults and exceptions; arthroscopy trocars appear under Rule 7. Ask the manufacturer for the classification rationale for the actual intended purpose and duration, plus the applicable conformity documentation. An arthroscopy example does not decide the classification of every abdominal access device.5
What does the safety literature establish about tip superiority?
The Cochrane review CD009814 included seven randomized studies with 654 participants; its evidence was current to May 2015. Sparse major complications and mostly very low-quality evidence prevented a reliable recommendation of one trocar type over another. This is historical evidence with substantial uncertainty, not proof that all current designs are equivalent. A claim about a specific modern model needs evidence applicable to that model and claim.6
Fuller and colleagues’ 2005 paper analyzed historical FDA reports received from 1 January 1997 to 30 June 2002. The original abstract describes missing device, procedure and event-timing details that limited investigation. It supports asking for traceability and complaint-handling evidence; it does not establish a current brand’s failure rate.7
FDA explains that MAUDE contains both mandatory and voluntary reports and that reports alone cannot establish incidence, prevalence or causation. Device-use frequency is unknown and reporting can be incomplete or biased. Do not rank suppliers by raw report totals or interpret an absence of reports as proof of safety. Bench fit and function evidence also cannot substitute for clinical evidence of reduced injury.8
The procurement consequence is to separate three questions: does the offered configuration meet the specification, is its market documentation adequate, and is a claimed clinical advantage substantiated? Passing one review does not answer the other two. Escalate an unsupported safety slogan for correction rather than converting it into a tender scoring advantage.
Which checks belong at receipt, and which need planned sample evaluation?
Set an agreed acceptance plan before the first commercial delivery. Unopened-pack inspection can identify visible damage and documentation mismatches, but cannot prove sterility or detect every packaging defect. The cited Stryker IFU instructs users not to use a device with damaged packaging. Any manufacturer-specific handling and inspection instructions must be checked for the product actually purchased.15
The distinction below is an editorial quality-planning recommendation. It is not a universal sampling rule, an annual testing mandate or a VEMERIX internal protocol. Quality staff should set the sampling plan, responsibilities, acceptance criteria and disposition process for the actual product and contract.
| Stage | Checks or evidence | Boundary and disposition |
|---|---|---|
| Commercial receipt | Purchase-order/reference match, quantities, lot and expiry details, destination labeling and agreed release documents. | Reconcile against the approved label and contract. Do not assume every jurisdiction requires identical symbols or a shipment-specific EO certificate. |
| Unopened-pack inspection | Visible shipping damage, punctures and obvious seal defects under the agreed inspection plan. | Visual inspection does not prove sterility or the absence of microleaks. Quarantine suspect units for quality review. |
| Packaging qualification | Applicable validation, aging/distribution evidence and any planned peel or integrity tests. | Opening, peel and destructive integrity tests belong to reserved evaluation samples, not checks on units returned to clinical stock.1, 2 |
| Functional qualification | Agreed dimensional, instrument-interface, optical, leak and retention assessments. | Use a qualified protocol and samples; define endpoints and criteria before testing. No generic pressure or pass limit is prescribed. |
| Release decision | Evidence reconciliation, deviations and responsible reviewer’s decision. | Keep unresolved material differences visible. Reassess affected evidence after a relevant configuration change. |
Source: Editorial acceptance-planning framework; FDA summaries distinguish bench and packaging evaluations. Actual controls depend on the manufacturer’s instructions, applicable requirements and buyer agreement.
Do not describe a peel test as non-destructive: it opens or disrupts the package. Keep opened or tested units out of sterile commercial and clinical inventory, identify them as evaluation samples and dispose of them under the agreed process. A supplier should not be asked to reseal a tested sample and present it as an untouched sterile unit.
What should the supplier return with the RFQ?
Use one response record for each offered configuration. Keep the commercial reference stable across the quote, sample label, drawing and document mapping. If the supplier changes a component or proposes an equivalent, require an updated record so the evaluation remains attached to what will actually be delivered.
- Offer: legal manufacturer, supplier, exact reference and revision; pack contents, unit of sale, quantities and quote date.
- Dimensions and interfaces: declared nominal size, actual dimensional drawing and measurement definitions, working length, supported instrument range and the intended instrument/scope models.
- Functional features: tip mechanism, optical capability, fixation, seal/reducer arrangement, gas connection and supplied accessories.
- Market evidence: target country, intended use, applicable documentation and a manufacturer mapping from the offered reference to document/page and current labeling.
- Evaluation evidence: configuration-specific reports or traceable summaries, representative-model rationale, planned sample evaluation and agreed acceptance criteria.
- Decision ownership: open question, named supplier responder, buyer clinical/quality/regulatory reviewer, due date and disposition.
The following worked audit uses actual public documents and catalog references. It records what those sources support and what remains unresolved; none of the rows represents a completed supplier audit or an approved purchase. The FDA and catalog rows are separate examples. No mapping between a CITEC reference and either clearance number is asserted.
| Public example | Verified source detail | Unresolved requirement | Buyer disposition |
|---|---|---|---|
| K231042 — bladeless subject device | Summary printed pp. 2 and 4: listed shaft diameters 5/10/12/15 mm; 100 mm shaft; abdominal/gynecologic indication.1 | Exact offered catalog reference, current label and evidence for the intended instrument combination. | Documented scope example only; obtain manufacturer mapping before accepting an offer. |
| K231042 — bladed subject device | Summary printed pp. 2 and 5: listed shaft diameters 5/10/12 mm; 100 mm shaft.1 | Any offered size, length or indication outside the described subject-device information. | Clarify the supporting regulatory rationale; do not borrow predicate details. |
| K190029 — family-name discrepancy | Database/letter name five families; linked indications and summary describe three.2 | Manufacturer explanation for the exact quoted variant and current labeling. | Request clarification; no finding of illegality is made. |
| CITEC CIT-WTL-12 | Catalog lists a longer bladeless 12 × 150 mm configuration.9 | Actual dimensions, target-market status and configuration-specific evaluation. | Catalog offering confirmed only; no clearance or clinical fit inferred. |
| CITEC CIT-GT-KIT05 | Catalog lists two 5 mm cannulas and one 5 mm obturator.9 | Complete current pack specification, clinical acceptance and applicable pack evidence. | Confirm contents and workflow with the supplier and clinical team. |
Source: FDA applicant summaries and CITEC catalog, checked 24 October 2026. Page references are printed summary pages, not PDF viewer page numbers. Editorial questions and dispositions are not test results.
Before award, assign each remaining question an owner. “Proceed to evaluation” means the line can enter the agreed review process; it does not mean it is cleared for clinical use by this guide. If a required configuration or market document cannot be substantiated, hold that line and request a corrected offer rather than silently filling an evidence gap.
How should buyers use and refresh this evidence?
NHS Supply Chain provides substantive neutral procurement material. Its archived technical specification, sections 3.9.5.1–3.9.5.3, lists trocar components, size categories and accessories. It is an example of procurement structure, not a worldwide size standard or the confirmed specification for the current contract.12
The separate current NHS framework runs from 10 August 2026 to 9 August 2028 and includes trocar and procedure-kit lots, with reusable/reposable options. This guide concentrates on disposable offers; it does not conclude that they are universally cheaper, clinically superior or environmentally preferable.13
Sources were reviewed on 24 October 2026. FDA decisions are dated examples with applicant-authored summaries, vendor listings are stated offerings, and the clinical studies have their own evidence windows. This documentary review did not measure samples, inspect a factory, compute registry market shares or create a price/compatibility database. Recheck the relevant documents whenever a quoted model, intended use, configuration, standard status or target market changes.
Where VEMERIX fits—and where due diligence still begins
VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.
This guide does not offer a VEMERIX trocar product or establish a Medison trocar manufacturing capability. Its purchasing framework applies to third-party offers. For broader sterile-device supplier questions, see the supplier qualification guide and VEMERIX’s quality and compliance information.
For a general portfolio or documentation enquiry, contact VEMERIX with the target market, intended product configuration and unresolved evidence questions. Product availability and any support scope need confirmation before a commercial commitment. No claim of third-party trocar validation or compatibility is made here.
Frequently asked questions
Does a 12 mm label establish compatibility with every 12 mm instrument?
No. The dimensional study shows that marketed categories do not standardize actual dimensions. Obtain the offered model’s drawing and supported range, then check the intended instrument and respective instructions. Treat an unverified combination as an evaluation question, not a demonstrated failure or pass.18
Can one clearance number establish every quoted configuration?
A clearance may cover a family, but a number alone does not explain the relationship of every offered reference to that family. Read the subject-device information and ask the manufacturer to reconcile the exact quote. Absence of a catalog reference from a public summary is not, by itself, proof that it is unauthorized.1, 2
Does optical access tell me whether a tip is bladeless?
Specify both fields. The cited IFU includes a bladeless optical design, showing that the features can coexist. It does not establish the tip mechanism or scope compatibility of another supplier’s model.15
Does citing YY/T 1710-2020 establish compliance or authorization?
No. The official record identifies a recommended standard and its scope. A supplier must substantiate applicable compliance and separately provide the relevant market documentation. This article does not confirm a current Chinese registration or clinical-evaluation exemption for an offered product.3, 4
Should every kit include the same accessories?
No universal kit composition is proposed here. Ask for the complete contents and have the clinical team decide whether they meet the approved workflow. Compare the resulting complete offers, including extra purchases and unused components, rather than assuming a kit is cheaper.
Can MAUDE reports rank the safest current trocar?
No. FDA identifies limitations that prevent report counts alone from establishing incidence or cause. Neither raw totals nor a zero-report claim provides a valid comparative safety ranking.8